Adulteration meeting set
This article was originally published in The Tan Sheet
Executive Summary
FDA schedules a May 1 public meeting to discuss methods for better predicting and preventing economically motivated adulteration of regulated products. The meeting in College Park, Md., will address what industry is doing and could do to prevent EMA. FDA, the U.S. Pharmacopeia and industry stakeholders are revising analytical testing standards to effectively screen for contaminated heparin, diethylene glycol in glycerin and melamine in infant formula - recent instances of EMA (1"The Tan Sheet" Feb. 16, 2009, p. 16)You may also be interested in...
U.S. Pharmacopeia Moves Melamine Testing Into The 21st Century
U.S. Pharmacopeia is developing a protein testing method that cannot be "tricked" by contaminants such as melamine, unlike the existing standard for analysis
Rare Disease Advocates Lobby US Congress For FDA Center of Excellence
Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.
FDA’s 2021 Budget Priorities For Cosmetics, Food Programs Include AI Use In Postmarket Oversight
FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: